Full Breakdown
US Launches Section 301 Probe into Germany’s Pharmaceutical Pricing
6/19/2026, 1:27:42 PM
Core Investigation – Trade Probe Initiated
On June 18-19, 2026, the U.S. Trade Representative (USTR) Jamieson Greer announced a Section 301 investigation into Germany’s pricing policies for innovative pharmaceuticals, part of President Donald Trump’s trade agenda. The probe will examine whether Germany’s plan to lower spending on new medicines constitutes an unreasonable or discriminatory trade practice. A docket for written comments opens June 25; a public hearing is set for September 22. Findings could lead to tariff measures on German imports.
Background & Context – German Health-Care Overhaul
In April 2026 the German Ministry of Health unveiled a statutory-health-insurance overhaul aimed at closing a €20 billion ($23 billion) funding gap. The plan introduces variable discounts on pharmaceuticals and fast-tracks legislation to curb spending on innovative drugs. Germany already has some of the highest drug prices in the EU. The proposal follows opposition from domestic pharma groups and has been revised.
Official Statements & Responses
USTR officials said American patients should not bear a disproportionate share of global pharmaceutical R&D costs and voiced concern over Germany’s fast-tracked legislation. German Health Minister Nina Warken said Germany was in a “general exchange” with the United States on pharmaceuticals. The VFA lobby warned the discount measures could erode Germany’s role in research, production and early availability of innovative medicines. PhRMA president Stephen Ubl welcomed the Section 301 action as a step to address unfair practices abroad.
Criticism & Opposition
German pharma groups, represented by the VFA lobby, argue the discount scheme would weaken the country’s position as a hub for drug research and risk hospital closures in some states. Regional lawmakers echo these worries, suggesting the reforms could compromise patient access and domestic innovation.
Conflicting Reports & Gaps
The German Embassy in Washington and the German Health Ministry declined to comment on the USTR probe, leaving details of the proposed discount mechanism unclear. The USTR has not disclosed any specific tariff rate or timeline.
Verbatim Quotes
- “I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals,” — Jamieson Greer, U.S. Trade Representative
- “has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,” — Jamieson Greer, U.S. Trade Representative
- “foreign governments have undervalued innovative medicines, forcing US patients and taxpayers to shoulder a disproportionate share of the costs of global innovation.” — Stephen Ubl, President, PhRMA
- “The proposed measures target the very areas where medical progress and future value creation originate: patent-protected, innovative medicines,” — VFA lobby, written opinion
What’s Next
The USTR will accept public comments until August 10 and hold a hearing on September 22. Depending on the outcome, the United States may impose tariffs on German imports or seek a negotiated settlement to align reimbursement practices with U.S. expectations.
